,Outcomes,Arm 1,Arm 2
0,intervention,ixabepilone,ixabepilone + EMP
1,Post-treatment declines in prostate-specific antigen of > or = 50 %,"21 of 44 patients ( 48 % ; 95 % CI , 33 % to 64 % )","31 of 45 patients ( 69 % ; 95 % CI , 55 % to 82 % )"
